FIG 9.
Prophylactic or delayed-start-to-treat effectiveness of VX-787 in the mouse influenza A/Viet Nam/1203/2004 (H5N1) virus infection model. Male BALB/c mice (8/group) were infected with a lethal challenge of influenza virus followed by administration of vehicle, oseltamivir, or VX-787 at the indicated doses and start times. The 21-day survival rate and percent BW loss (means ± SEM) are shown. The shaded area represents the treatment period.